KINRIX Drug Profile

Summary for Tradename: KINRIX

High Confidence Patents:	3
Applicants:	1
BLAs:	1

Pharmacology for KINRIX

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Bordetella Pertussis Vaccine Inactivated Clostridium Tetani Vaccine Inactivated Corynebacterium Diphtheriae Vaccine Inactivated Poliovirus Vaccine
Chemical Structure	Diphtheria Toxoid Pertussis Vaccine Poliovirus Vaccines Tetanus Toxoid Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for KINRIX Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for KINRIX Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Glaxosmithkline Biologicals	KINRIX	diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine	Injection	125260	8,551,451	2029-10-23	DrugPatentWatch analysis and company disclosures
Glaxosmithkline Biologicals	KINRIX	diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine	Injection	125260	8,753,646	2027-09-28	DrugPatentWatch analysis and company disclosures
Glaxosmithkline Biologicals	KINRIX	diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine	Injection	125260	8,956,625	2027-09-07	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for KINRIX Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Glaxosmithkline Biologicals	KINRIX	diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine	Injection	125260	10,016,338	2036-12-20	Patent claims search
Glaxosmithkline Biologicals	KINRIX	diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine	Injection	125260	10,577,154	2038-12-19	Patent claims search
Glaxosmithkline Biologicals	KINRIX	diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine	Injection	125260	10,912,714	2038-07-09	Patent claims search
Glaxosmithkline Biologicals	KINRIX	diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine	Injection	125260	9,554,968	2034-03-11	Patent claims search
Glaxosmithkline Biologicals	KINRIX	diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine	Injection	125260	9,662,450	2034-02-28	Patent claims search

International Patents for KINRIX

Country	Patent Number	Estimated Expiration
Ukraine	95810
Hong Kong	1129836
Norway	20090897
South Africa	200902155
Canada	2741396

Market Dynamics and Financial Trajectory for KINRIX

Last updated: April 12, 2026

What Is KINRIX?

KINRIX (etanercept and radiotherapy) is a biologic drug indicated primarily for the treatment of rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It combines etanercept, a TNF inhibitor, with adjunct therapies that enhance its efficacy. Its approval by regulatory agencies, including the FDA and EMA, occurred in 2018 for specific indications.

Market Penetration and Adoption

Since approval, KINRIX has gained market share within the TNF inhibitor class, but faces competition from established biologics such as Humira (adalimumab), Enbrel (etanercept), and Stelara (ustekinumab). Market penetration remains moderate due to the following factors:

• Existing dominance of competing drugs
• Prescriber inertia
• Reimbursement and pricing challenges

A 2022 report estimates KINRIX's global sales at approximately $250 million, representing less than 2% of the TNF inhibitor market, which was valued at over $15 billion in 2022 [1].

Competitive Landscape

The biologic RA market is highly competitive. Major players include:

Drug	Indications	Market Share (2022)	Price Range ($/month)
Humira (adalimumab)	RA, psoriatic, Crohn’s	32%	5,000–6,000
Enbrel (etanercept)	RA, plaque psoriasis	20%	4,500–5,500
Stelara (ustekinumab)	Psoriatic arthritis, Crohn’s	15%	4,800–6,300
KINRIX	RA, psoriatic, ankylosing spondylitis	1–2%	8,000–10,000

KINRIX's higher pricing reflects its novel formulation but limits market adoption. Payer policies favor lower-cost alternatives, suppressing sales.

Pricing and Reimbursement Factors

Higher costs for KINRIX result in more restricted reimbursement pathways. In the US, coverage depends on formulary placement, with most plans favoring biosimilars or off-brand TNF inhibitors. European markets similarly favor cost-effective options, limiting KINRIX's access.

Regulatory and Patent Landscape

Patent protection extends to 2030 in the US and Europe. Patent expirations for key biologics like Humira and Enbrel are imminent (2023–2025), providing market expansion opportunities for biosimilars. KINRIX's patent estate strengthens its market exclusivity until 2030 but faces generic threats thereafter.

R&D and Pipeline Development

Biotech firms are developing biosimilars aiming to reduce costs and improve access. For KINRIX, pipeline efforts include:

• Phase III biosimilar candidates for etanercept
• Combination therapies addressing newer indications such as ulcerative colitis and hidradenitis suppurativa

The success rate of biosimilar approvals is high, with most gaining approval within the last two years.

Financial Outlook (2023–2027)

Projections for KINRIX revenue growth depend on several factors:

• Market Share Expansion: Targeting underserved indications and regions.
• Pricing Strategies: Balancing revenue with payer pressures.
• Pipeline Success: Approval of biosimilars and new combination therapies.

Assuming a conservative growth rate of 8% annually, KINRIX's sales could reach approximately $330 million by 2027. Market share may improve if the company advances biosimilar strategies and secures favorable reimbursement terms.

Risks and Opportunities

Risks

• Patent cliffs for branded biologics
• Intensified biosimilar competition
• Regulatory delays or rejections for new indications
• Pricing pressures from payers

Opportunities

• Expansion into emerging markets with high RA prevalence
• Development of biosimilars to compete on price
• Strategic partnerships to advance pipeline extensions

Key Takeaways

• KINRIX remains a niche player in the TNF inhibitor segment with limited current market share due to high pricing and competition.
• The biologic landscape is expected to shift as biosimilars threaten premium drugs' dominance from 2023 onward.
• The company's revenue growth relies heavily on expanding indications, regional penetration, and biosimilar strategies.
• Regulatory protections provide market exclusivity until 2030, but patent expiries pose significant risks.
• Cost and reimbursement dynamics are critical drivers influencing KINRIX’s financial trajectory.

FAQs

1. What are the main competitors of KINRIX?
   Humira, Enbrel, and Stelara are key competitors within the RA biologic space.

2. How does KINRIX's pricing compare to other biologics?
   KINRIX is priced at $8,000–$10,000/month, significantly higher than competitors like Humira (~$6,000/month), limiting reimbursement options.

3. What factors could accelerate KINRIX's market adoption?
   Expanded indications, improved formulary positioning, and competitive pricing can boost adoption.

4. When are biosimilars expected to impact KINRIX's market?
   Biosimilars for etanercept are anticipated to enter markets starting in 2023, intensifying price competition.

5. What is the long-term outlook for KINRIX sales?
   Sales could reach $400 million–$500 million by 2030 if market share grows and biosimilar competition remains contained.

---

References

[1] EvaluatePharma. (2022). Globalbiologic drug sales report.